ERBB2 and breast carcinoma: We tried to apply the iPS to the four breast cancer (BRCA) subtypes separately to explore whether the disruption of pathways occurs in the subtypes of breast cancer, and 2, 1, 7, and 1 significant biomarker pathways were identified in the basal-like, HER2+, luminal A, and luminal B subtypes, respectively (Table S3).